ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 559

Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis

Josef S. Smolen1, Young Mo Kang2, Wan-Hee Yoo3, Paul Emery4, Michael E Weinblatt5, Edward C. Keystone6, Mark C. Genovese7, Gihyun Myung8, Evelyn Hong8, Inyoung Baek8 and Jeehoon Ghil8, 1Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, 2Kyungpook National University School of Medicine, Daegu, Korea, Republic of (South), 3Chonbuk National University School of Medicine, Jeonju, Korea, Republic of (South), 4University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, 5Brigham and Women's Hospital, Boston, MA, 6Mount Sinai Hospital, Toronto, ON, Canada, 7Stanford University Medical Center, Palo Alto, CA, 8Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, Biologics, biosimilars, radiography and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: SB4, SB2, and SB5 are biosimilars of reference etanercept, infliximab, and adalimumab, respectively. Radiographic data were assessed using the modified Total Sharp Score (mTSS) at week 0 and final week (week 52 for etanercept and adalimumab and week 54 for infliximab) in phase III biosimilar studies.1-3 The purpose of this analysis is to identify baseline demographics and disease characteristics that are associated with radiographic progression (RP) and build a matrix model to show the proportion of patients with RP by the identified baseline factors.

Methods: Patients who had radiographic data were pooled. RP was defined as a change in mTSS >0 from week 0 to final week. The three baseline factors that had the strongest Pearson¡¯s correlation coefficient with the change in mTSS were selected, and univariate logistic regression analysis was performed to assess the association between each baseline factor and predicted probability of patients with RP. Then, multivariate logistic model was fitted to develop a matrix that shows the proportion of patients with RP in each tertile of baseline factors.

Results: A total of 1371 patients had radiographic assessments. The mean change in mTSS was 0.41 and the number of patients who had RP was 376 patients (27.4%). The swollen joint count 28 ([SJC28], p-value = 0.0041), C-reactive protein ([CRP], p-value = 0.033), and Physician Global Assessment ([PhGA], p-value = 0.048) had the strongest correlation with RP (Table 1). Predicted probability of patients with RP as a function of SJC28, CRP, and PhGA is displayed in Figure 1. The proportion of patients with RP increased as baseline levels of each factor worsened (Figure 2). The proportion of patients with RP was greatest (37%, 95% CI: 32, 43) in the highest tertile of each category (SJC28 >17, CRP >30, and PhGA >80) and least (12%, 95% CI: 8, 20) in the lowest tertile of each category (SJC28< 10, CRP <5, and PhGA <50).  

Conclusion: A pooled radiographic assessment data showed that baseline SJC28, CRP, and PhGA are associated with RP, and the proportion of patients with RP increases as each baseline factor worsened.  

 References

  1. Smolen JS et al. Rheumatology. 2017 Oct 1;56(10):1771-1779
  2. Weinblatt ME et al. Arthritis Rheumatol. 2018; Jan;70(1):40-48
  3. Weinblatt ME et al. Arthritis Rheumatol. doi: 10.1002/art.40444


Disclosure: J. S. Smolen, AbbVie, Janssen, MSD, Pfizer, Roche, and UCB, 2,AbbVie, Amgen, AstraZeneca, Astro-Pharma, Celgene, GSK, Janssen, Lilly, Medimmune, MSD, Novartis-Sandoz, Novo Nordisk, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB, 5; Y. M. Kang, None; W. H. Yoo, None; P. Emery, Pfizer,MSD,Abbvie,BMS,UCB,Roche,Novartis,Samsung, Sandoz and Lilly, 2, 5, 8; M. E. Weinblatt, Amgen, Bristol-Myers Squibb, Crescendo Bioscience, and Sanofi/Regeneron, 2,AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Corrona, GSK, Gilead, Lilly, Lycera, Merck, Novartis, Pfizer, Roche, Samsung Bioepis, Set Point, and UCB, 5,Lycera, Canfite, Scipher, Vorso, and Inmedix, 1; E. C. Keystone, Abbott, AstraZeneca, Bristol-Myers Squibb, Crescendo Bioscience, F. Hoffmann-La Roche, Genentech, Janssen, Lilly, Merck, Pfizer, UCB, Samsung Bioepis, 5; M. C. Genovese, Samsung, Merck, Abbvie, Amgen, BI, 5; G. Myung, Samsung Bioepis, 3; E. Hong, Samsung Bioepis, 3; I. Baek, Samsung Bioepis, 3; J. Ghil, Samsung Bioepis, 3.

To cite this abstract in AMA style:

Smolen JS, Kang YM, Yoo WH, Emery P, Weinblatt ME, Keystone EC, Genovese MC, Myung G, Hong E, Baek I, Ghil J. Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/radiographic-progression-based-on-baseline-demographics-and-disease-characteristics-from-three-tnf-alpha-inhibitor-biosimilar-studies-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/radiographic-progression-based-on-baseline-demographics-and-disease-characteristics-from-three-tnf-alpha-inhibitor-biosimilar-studies-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology